Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma

Abstract

Our results suggest that MTV measured by (18)F-FDG PET/CT has independent prognostic value of in patients with HNSCC, stronger than SUVmax.

Prognostic evaluation of percentage variation of metabolic tumor burden calculated by dual‐phase 18FDG PET‐CT imaging in patients with head and neck cancer

“…This reconfirms prior reports of MTV as an independent prognostic factor in the treatment of HNSCC with higher performance than SUVmax. For example, we proved that a MTV >4.9 mL using an absolute SUV threshold of 5.0 significantly predicted a poor event‐free survival (HR = 6.2; p = .011) in a previous study concerning 80 consecutive patients with HNSCC . The difference of cutoff volume between these 2 series can be explained by the fact that we have chosen a threshold of 40% SUVmax to evaluate MTV in accordance with others studies .…”

“…Therefore, 2 new concepts have recently been developed to improve 18 FDG PET‐CT prognostic value in solid cancers: one is based on metabolic tumor burden evaluation, the other is based on 18 FDG RI calculated by using dual‐phase PET acquisition method . Our team have already suggested that MTV or RI were more relevant prognostic indicators than SUVmax in HNSCC . To date, no series has studied and compared together in a same cohort the prognostic value of kinetic and volumetric PET parameters.…”

Diagnostic performance of 18fluorodesoxyglucose positron emission/computed tomography and magnetic resonance imaging in detecting T1‐T2 head and neck squamous cell carcinoma

“…Moreover, recent studies have shown a higher prognostic significance of MTV to predict survival in patients with HNSCC. Our group has also proven in several prospective series that pretreatment MTV was an independent predictive factor for recurrence free survival, unlike SUV MAX and T stage in multivariate analysis …”

“…To detect head and neck squamous cell carcinoma (HNSCC) early remains a real challenge, with prognostic implications for patients. From our previous experience, patients with T1‐T2 lesions at diagnosis according to WHO classification have a significantly better 3‐year overall survival (69%) than those with locally advanced‐stage presentations (41%) . Because small lesions are frequently clinically asymptomatic, imaging should play an important role in their diagnosis, especially with constant advances in technology.…”

“…Lesions staged T1‐T2 according the World Health Organization (WHO) classification are frequently clinically asymptomatic and also misdiagnosed due to their small size . However, patients with T1‐T2 lesions at diagnosis have a significantly better prognosis than those with a locally advanced stage . To detect HNSCC at an early stage remains a real challenge, particularly with medical imaging.…”